Axsome Therapeutics' stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth, but I maintain a "sell" rating. Despite Auvelity's revenue growth, significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback